Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

First randomized trial to confirm Her1/EGFR inhibitor prolongs survival in NSCLC after chemotherapy

June 22, 2004

OGX-O11 potently inhibits clusterin expression in prostate cancer

June 22, 2004

Merck researchers describe new protein kinase inhibitors and their use

June 21, 2004

Novel inhibitors of Src kinases developed at Roche

June 21, 2004

New phase II trial studies talabostat for advanced metastatic melanoma

June 21, 2004

ILX-651 in new phase II trial for hormone-refractory prostate cancer

June 21, 2004

New CDK inhibitors in early development at Banyu

June 18, 2004

Antiangiogenic HARP-derived peptides newly developed at CNRS

June 18, 2004

Labopharm to apply polymeric nanodelivery systems technology to cancer drug

June 18, 2004

Phase II trial of Xcytrin for recurrent low-grade NHL under way

June 18, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...